Publications by authors named "Marek Krogulec"

Claim this Profile
C
Correction to: Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability Study.
Mark G Lebwohl, John Y Koo, Janusz Jaworski, Jakub Trefler, Stefan Daniluk, Marek Krogulec

Adv Ther· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Biosimilar CT-P47 Versus Reference Tocilizumab: 1-Year Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study in Patients with Rheumatoid Arthritis.
Gerd Burmester, Jakub Trefler, Artur Racewicz, Janusz Jaworski, Agnieszka Zielińska, Marek Krogulec

Clin Drug Investig· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CT-P17 Adalimumab Biosimilar in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: An Open-Label Extension of a Phase 3 Interchangeability Study.
David M Pariser, Mark G Lebwohl, Janusz Jaworski, Jakub Trefler, Stefan Daniluk, Marek Krogulec

Dermatol Ther (Heidelb)· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability Study.
Mark G Lebwohl, John Y Koo, Janusz Jaworski, Jakub Trefler, Stefan Daniluk, Marek Krogulec

Adv Ther· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks of switching data from reference tocilizumab to CT-P47.
Josef S Smolen, Jakub Trefler, Artur Racewicz, Janusz Jaworski, Agnieszka Zielińska, Marek Krogulec

RMD Open· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and/or anti-TNFα therapy: a placebo-controlled phase II study.
Claire Daien, Marek Krogulec, Paul Gineste, Jean-Marc Steens, Laurence Desroys du Roure

Ann Rheum Dis· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomized, double-blind study in rheumatoid arthritis.
Daniel E Furst, Janusz Jaworski, Rafal Wojciechowski, Piotr Wiland, Anna Dudek, Marek Krogulec

Rheumatology (Oxford)· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study.
Jonathan Kay, Janusz Jaworski, Rafal Wojciechowski, Piotr Wiland, Anna Dudek, Marek Krogulec

Arthritis Res Ther· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial.
Chang-Hee Suh, Dae Hyun Yoo, Alfredo Berrocal Kasay, Elia Chalouhi El-Khouri, Francisco Fidenci Cons Molina, Marek Krogulec

BioDrugs· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baricitinib in Patients with Refractory Rheumatoid Arthritis.
Mark C Genovese, Joel Kremer, Omid Zamani, Charles Ludivico, Marek Krogulec

N Engl J Med· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained remission with etanercept tapering in early rheumatoid arthritis.
Paul Emery, Mohammed Hammoudeh, Oliver FitzGerald, Bernard Combe, Emilio Martin-Mola, Marek Krogulec

N Engl J Med· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis